News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: revenue_monster post# 255394

Sunday, 02/28/2016 9:08:03 AM

Sunday, February 28, 2016 9:08:03 AM

Post# of 347009

they dont even know dosing strategies that will work etc.



you must be joking rev monster.... no dosing strategies?? They just doubled MOS in the phase II and the Bavi+Doce arm in Sunrise was "GOING AS EXPECTED" with no problems in the Bavi arm...

When you have a platform with hardly no side effects.... dosing becomes less and less of an issue.

I wonder what dosing strategy NCCN will come up with

You seem to forget about those studies going on ??? : )

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y